Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug
Cigna accused Bristol Myers Squibb of violating antitrust law by keeping generic versions of its blood cancer drug Pomalyst off the market to retain a monopoly.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Bristol Myers
since
auto-detected in 48 stories
39 hours ago
27 days ago
Why the stock rally fizzled — plus, our latest thinking on Goldman and Bristol Myers
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
62 days ago
Why we're lowering our Bristol Myers price target despite an earnings beat, guidance raise
Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.
3 months ago
JPMorgan says own this drug stock. It's one Jim Cramer is itching to buy again
The Club remains optimistic about Bristol Myers and shares JPMorgan's enthusiasm about Cobenfy.
page 1 of 1